Stem cell transplantation for myelofibrosis: A report from two Canadian centers

Bone Marrow Transplantation

Volumn 32, Issue 1, 2003, Pages 35-40

  Daly, A ^a   Song, K ^b   Nevill, T ^b   Nantel, S ^b   Toze, C ^b   Hogge, D ^b   Forrest, D ^b   Lavoie, J ^b   Sutherland, H ^b   Shepherd, J ^b   Hasegawa, W ^a   Lipton, J ^a   Messner, H ^a   Kiss, T ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Agnogenic myeloid metaplasia; Allogeneic; Essential thrombocytosis; Graft versus host disease; Myelofibrosis; Stem cell transplant; Transfusion requirements

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE FACILITY; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; LIVER VENOOCCLUSIVE DISEASE; MALE; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; SPLENECTOMY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTOSIS;

ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; SPLENECTOMY; SURVIVAL ANALYSIS; THROMBOCYTOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 10744225447     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704075     Document Type: Article

References (28)

1. Reilly JT. Pathogenesis and management of idiopathic myelofibrosis. Baillieres Clin Hematol 1998; 11: 751-767.
2. Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Blood Rev 2000; 14: 121-129.
3. Smith BD, Moliterno AR. Biology and management of idiopathic myelofibrosis. Curr Opin Oncol 2001; 13: 91-94.
4. Popplewell L, Forman SJ. Allogeneic hematopoietic stem cell transplantation for acute leukemia, chronic leukemia and myelodysplasia. Hematol Oncol Clin North Am 1999; 13: 987-1015.
5. Anderson JE, Sale G, Appelbaum FR et al. Allogeneic marrow transplantion for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010-1016.
6. Singhal S, Powles R, Treleaven J et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16: 743-746.
7. De Revel T, Giraudier S, Nedellec G et al. Allogeneic bone marrow transplantation for postpolycythemic myeloid metaplasia with myelofibrosis: a case report. Bone Marrow Transplant 1995; 16: 187-189.
8. Bullorsky EO, Shanley CM, Stemmelin G et al. Acute megakaryoblastic leukemia with massive myelofibrosis: complete remission and reversal of marrow fibrosis with allogeneic bone marrow transplantation as the only treatment. Bone Marrow Transplant 1990; 6: 449-452.
9. Dokal I, Jones L, Deenmamode M et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1989; 71: 158-160.
10. Rajantie J, Sale GE, Deeg HJ et al. Adverse effect of severe marrow fibrosis on hematological recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986; 67: 1693-1697.
11. Soll E, Massumoto C, Clift RA et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667-4673.
12. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954-2970.
13. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
14. Appelbaum FR, Dahlberg S, Thomas ED et al. Bone marrow transplantation or chemotherapy after remission induction in adults with acute non-lymphoblastic leukemia. Ann Intern Med 1984; 101: 581-588.
15. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
16. Storb R, Deeg HJ, Farewell V et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
17. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
18. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
19. McDonald GB, Sharma P, Matthews DE et al. Venoocclusive disease of the liver following allogeneic bone marrow transplantation: diagnosis incidence and predisposing factors. Hepatology 1984; 4: 116-122.
20. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0 (CTC, v2.0), publish date April 30, 1999.
21. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018.
22. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Guardiarola P, Anderson JE, Bandini G et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto de Midollo Osseo and Fred Hutchinson Cancer Research Center collaborative study. Blood 1999; 93: 2831-2838.
24. Weinstein IM. Idiopathic myelofibrosis: historical review, diagnosis and management. Blood Rev. 1991; 5: 98-104.
25. Michallet M, Corront B, Bosson JL et al. Role of splenectomy on incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients. Bone Marrow Transplant 1991; 8: 13-17.
26. Ringden O, Nilsson B. Death by graft-versus-host disease is associated with HLA-mismatch, high recipient age, low marrow cell dose and splenectomy. Transplantation 1985; 40: 39-44.
27. Xenocostas A, Yee A, Wong CJ et al. Red blood cell transfusion requirements after allogeneic bone marrow transplantation: impact of the pre-transplant hemoglobin level on transfusion and early survival. Transfusion 2003; 43: 373-382.
28. Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255-2258.